▶ 調査レポート

抗がん剤曝露評価サービスのグローバル市場展望 2023年-2029年:がん標的治療薬、免疫療法薬、その他

• 英文タイトル:Anti-cancer Drug Exposure Evaluation Services Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが調査・発行した産業分析レポートです。抗がん剤曝露評価サービスのグローバル市場展望 2023年-2029年:がん標的治療薬、免疫療法薬、その他 / Anti-cancer Drug Exposure Evaluation Services Market, Global Outlook and Forecast 2023-2029 / MMG23DC12244資料のイメージです。• レポートコード:MMG23DC12244
• 出版社/出版日:Market Monitor Global / 2023年12月
• レポート形態:英語、PDF、85ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User(1名様閲覧用)¥481,000 (USD3,250)▷ お問い合わせ
  Multi User(20名様閲覧用)¥625,300 (USD4,225)▷ お問い合わせ
  Enterprise User(閲覧人数制限なし)¥721,500 (USD4,875)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートは次の情報を含め、世界の抗がん剤曝露評価サービス市場規模と予測を収録しています。・世界の抗がん剤曝露評価サービス市場:売上、2018年-2023年、2024年-2029年
・世界の抗がん剤曝露評価サービス市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の抗がん剤曝露評価サービス市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「がん標的治療薬」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

抗がん剤曝露評価サービスのグローバル主要企業は、IQVIA、 Labcorp、 PPD、 ICON、 Parexel、 Celerion、 Syneos Health、 WuXi AppTec、 Frontage Laboratoriesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、抗がん剤曝露評価サービスのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の抗がん剤曝露評価サービス市場:タイプ別、2018年-2023年、2024年-2029年
世界の抗がん剤曝露評価サービス市場:タイプ別市場シェア、2022年
・がん標的治療薬、免疫療法薬、その他

世界の抗がん剤曝露評価サービス市場:用途別、2018年-2023年、2024年-2029年
世界の抗がん剤曝露評価サービス市場:用途別市場シェア、2022年
・薬局、病院、外来化学療法エリア

世界の抗がん剤曝露評価サービス市場:地域・国別、2018年-2023年、2024年-2029年
世界の抗がん剤曝露評価サービス市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における抗がん剤曝露評価サービスのグローバル売上、2018年-2023年
・主要企業における抗がん剤曝露評価サービスのグローバル売上シェア、2022年
・主要企業における抗がん剤曝露評価サービスのグローバル販売量、2018年-2023年
・主要企業における抗がん剤曝露評価サービスのグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
IQVIA、 Labcorp、 PPD、 ICON、 Parexel、 Celerion、 Syneos Health、 WuXi AppTec、 Frontage Laboratories

*************************************************************

・調査・分析レポートの概要
抗がん剤曝露評価サービス市場の定義
市場セグメント
世界の抗がん剤曝露評価サービス市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の抗がん剤曝露評価サービス市場規模
世界の抗がん剤曝露評価サービス市場規模:2022年 VS 2029年
世界の抗がん剤曝露評価サービス市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの抗がん剤曝露評価サービスの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の抗がん剤曝露評価サービス製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:がん標的治療薬、免疫療法薬、その他
抗がん剤曝露評価サービスのタイプ別グローバル売上・予測

・用途別市場分析
用途区分:薬局、病院、外来化学療法エリア
抗がん剤曝露評価サービスの用途別グローバル売上・予測

・地域別市場分析
地域別抗がん剤曝露評価サービス市場規模 2022年と2029年
地域別抗がん剤曝露評価サービス売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
IQVIA、 Labcorp、 PPD、 ICON、 Parexel、 Celerion、 Syneos Health、 WuXi AppTec、 Frontage Laboratories
...

This research report provides a comprehensive analysis of the Anti-cancer Drug Exposure Evaluation Services market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Anti-cancer Drug Exposure Evaluation Services market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Anti-cancer Drug Exposure Evaluation Services, challenges faced by the industry, and potential opportunities for market players.
The global Anti-cancer Drug Exposure Evaluation Services market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Anti-cancer Drug Exposure Evaluation Services market presents opportunities for various stakeholders, including Pharmacy, Hospital. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Anti-cancer Drug Exposure Evaluation Services market. Additionally, the growing consumer demand present avenues for market expansion.
The global Anti-cancer Drug Exposure Evaluation Services market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the Anti-cancer Drug Exposure Evaluation Services market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Anti-cancer Drug Exposure Evaluation Services market.
Market Overview: The report provides a comprehensive overview of the Anti-cancer Drug Exposure Evaluation Services market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Targeted Cancer Drugs, Immunotherapy Drugs), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Anti-cancer Drug Exposure Evaluation Services market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Anti-cancer Drug Exposure Evaluation Services market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Anti-cancer Drug Exposure Evaluation Services market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Anti-cancer Drug Exposure Evaluation Services market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Anti-cancer Drug Exposure Evaluation Services market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Anti-cancer Drug Exposure Evaluation Services market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Anti-cancer Drug Exposure Evaluation Services, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Anti-cancer Drug Exposure Evaluation Services market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Anti-cancer Drug Exposure Evaluation Services market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Targeted Cancer Drugs
Immunotherapy Drugs
Other
Market segment by Application
Pharmacy
Hospital
Out-Patient Chemotherapy Area
Global Anti-cancer Drug Exposure Evaluation Services Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
IQVIA
Labcorp
PPD
ICON
Parexel
Celerion
Syneos Health
WuXi AppTec
Frontage Laboratories
Outline of Major Chapters:
Chapter 1: Introduces the definition of Anti-cancer Drug Exposure Evaluation Services, market overview.
Chapter 2: Global Anti-cancer Drug Exposure Evaluation Services market size in revenue.
Chapter 3: Detailed analysis of Anti-cancer Drug Exposure Evaluation Services company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-cancer Drug Exposure Evaluation Services in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

レポート目次

1 Introduction to Research & Analysis Reports
1.1 Anti-cancer Drug Exposure Evaluation Services Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Anti-cancer Drug Exposure Evaluation Services Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Anti-cancer Drug Exposure Evaluation Services Overall Market Size
2.1 Global Anti-cancer Drug Exposure Evaluation Services Market Size: 2022 VS 2029
2.2 Global Anti-cancer Drug Exposure Evaluation Services Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Anti-cancer Drug Exposure Evaluation Services Players in Global Market
3.2 Top Global Anti-cancer Drug Exposure Evaluation Services Companies Ranked by Revenue
3.3 Global Anti-cancer Drug Exposure Evaluation Services Revenue by Companies
3.4 Top 3 and Top 5 Anti-cancer Drug Exposure Evaluation Services Companies in Global Market, by Revenue in 2022
3.5 Global Companies Anti-cancer Drug Exposure Evaluation Services Product Type
3.6 Tier 1, Tier 2 and Tier 3 Anti-cancer Drug Exposure Evaluation Services Players in Global Market
3.6.1 List of Global Tier 1 Anti-cancer Drug Exposure Evaluation Services Companies
3.6.2 List of Global Tier 2 and Tier 3 Anti-cancer Drug Exposure Evaluation Services Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Anti-cancer Drug Exposure Evaluation Services Market Size Markets, 2022 & 2029
4.1.2 Targeted Cancer Drugs
4.1.3 Immunotherapy Drugs
4.1.4 Other
4.2 By Type – Global Anti-cancer Drug Exposure Evaluation Services Revenue & Forecasts
4.2.1 By Type – Global Anti-cancer Drug Exposure Evaluation Services Revenue, 2018-2023
4.2.2 By Type – Global Anti-cancer Drug Exposure Evaluation Services Revenue, 2024-2029
4.2.3 By Type – Global Anti-cancer Drug Exposure Evaluation Services Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Anti-cancer Drug Exposure Evaluation Services Market Size, 2022 & 2029
5.1.2 Pharmacy
5.1.3 Hospital
5.1.4 Out-Patient Chemotherapy Area
5.2 By Application – Global Anti-cancer Drug Exposure Evaluation Services Revenue & Forecasts
5.2.1 By Application – Global Anti-cancer Drug Exposure Evaluation Services Revenue, 2018-2023
5.2.2 By Application – Global Anti-cancer Drug Exposure Evaluation Services Revenue, 2024-2029
5.2.3 By Application – Global Anti-cancer Drug Exposure Evaluation Services Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Anti-cancer Drug Exposure Evaluation Services Market Size, 2022 & 2029
6.2 By Region – Global Anti-cancer Drug Exposure Evaluation Services Revenue & Forecasts
6.2.1 By Region – Global Anti-cancer Drug Exposure Evaluation Services Revenue, 2018-2023
6.2.2 By Region – Global Anti-cancer Drug Exposure Evaluation Services Revenue, 2024-2029
6.2.3 By Region – Global Anti-cancer Drug Exposure Evaluation Services Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Anti-cancer Drug Exposure Evaluation Services Revenue, 2018-2029
6.3.2 US Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.3.3 Canada Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.3.4 Mexico Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Anti-cancer Drug Exposure Evaluation Services Revenue, 2018-2029
6.4.2 Germany Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.4.3 France Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.4.4 U.K. Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.4.5 Italy Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.4.6 Russia Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.4.7 Nordic Countries Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.4.8 Benelux Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Anti-cancer Drug Exposure Evaluation Services Revenue, 2018-2029
6.5.2 China Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.5.3 Japan Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.5.4 South Korea Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.5.5 Southeast Asia Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.5.6 India Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Anti-cancer Drug Exposure Evaluation Services Revenue, 2018-2029
6.6.2 Brazil Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.6.3 Argentina Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Anti-cancer Drug Exposure Evaluation Services Revenue, 2018-2029
6.7.2 Turkey Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.7.3 Israel Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.7.4 Saudi Arabia Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
6.7.5 UAE Anti-cancer Drug Exposure Evaluation Services Market Size, 2018-2029
7 Anti-cancer Drug Exposure Evaluation Services Companies Profiles
7.1 IQVIA
7.1.1 IQVIA Company Summary
7.1.2 IQVIA Business Overview
7.1.3 IQVIA Anti-cancer Drug Exposure Evaluation Services Major Product Offerings
7.1.4 IQVIA Anti-cancer Drug Exposure Evaluation Services Revenue in Global Market (2018-2023)
7.1.5 IQVIA Key News & Latest Developments
7.2 Labcorp
7.2.1 Labcorp Company Summary
7.2.2 Labcorp Business Overview
7.2.3 Labcorp Anti-cancer Drug Exposure Evaluation Services Major Product Offerings
7.2.4 Labcorp Anti-cancer Drug Exposure Evaluation Services Revenue in Global Market (2018-2023)
7.2.5 Labcorp Key News & Latest Developments
7.3 PPD
7.3.1 PPD Company Summary
7.3.2 PPD Business Overview
7.3.3 PPD Anti-cancer Drug Exposure Evaluation Services Major Product Offerings
7.3.4 PPD Anti-cancer Drug Exposure Evaluation Services Revenue in Global Market (2018-2023)
7.3.5 PPD Key News & Latest Developments
7.4 ICON
7.4.1 ICON Company Summary
7.4.2 ICON Business Overview
7.4.3 ICON Anti-cancer Drug Exposure Evaluation Services Major Product Offerings
7.4.4 ICON Anti-cancer Drug Exposure Evaluation Services Revenue in Global Market (2018-2023)
7.4.5 ICON Key News & Latest Developments
7.5 Parexel
7.5.1 Parexel Company Summary
7.5.2 Parexel Business Overview
7.5.3 Parexel Anti-cancer Drug Exposure Evaluation Services Major Product Offerings
7.5.4 Parexel Anti-cancer Drug Exposure Evaluation Services Revenue in Global Market (2018-2023)
7.5.5 Parexel Key News & Latest Developments
7.6 Celerion
7.6.1 Celerion Company Summary
7.6.2 Celerion Business Overview
7.6.3 Celerion Anti-cancer Drug Exposure Evaluation Services Major Product Offerings
7.6.4 Celerion Anti-cancer Drug Exposure Evaluation Services Revenue in Global Market (2018-2023)
7.6.5 Celerion Key News & Latest Developments
7.7 Syneos Health
7.7.1 Syneos Health Company Summary
7.7.2 Syneos Health Business Overview
7.7.3 Syneos Health Anti-cancer Drug Exposure Evaluation Services Major Product Offerings
7.7.4 Syneos Health Anti-cancer Drug Exposure Evaluation Services Revenue in Global Market (2018-2023)
7.7.5 Syneos Health Key News & Latest Developments
7.8 WuXi AppTec
7.8.1 WuXi AppTec Company Summary
7.8.2 WuXi AppTec Business Overview
7.8.3 WuXi AppTec Anti-cancer Drug Exposure Evaluation Services Major Product Offerings
7.8.4 WuXi AppTec Anti-cancer Drug Exposure Evaluation Services Revenue in Global Market (2018-2023)
7.8.5 WuXi AppTec Key News & Latest Developments
7.9 Frontage Laboratories
7.9.1 Frontage Laboratories Company Summary
7.9.2 Frontage Laboratories Business Overview
7.9.3 Frontage Laboratories Anti-cancer Drug Exposure Evaluation Services Major Product Offerings
7.9.4 Frontage Laboratories Anti-cancer Drug Exposure Evaluation Services Revenue in Global Market (2018-2023)
7.9.5 Frontage Laboratories Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Anti-cancer Drug Exposure Evaluation Services Market Opportunities & Trends in Global Market
Table 2. Anti-cancer Drug Exposure Evaluation Services Market Drivers in Global Market
Table 3. Anti-cancer Drug Exposure Evaluation Services Market Restraints in Global Market
Table 4. Key Players of Anti-cancer Drug Exposure Evaluation Services in Global Market
Table 5. Top Anti-cancer Drug Exposure Evaluation Services Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Anti-cancer Drug Exposure Evaluation Services Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Anti-cancer Drug Exposure Evaluation Services Revenue Share by Companies, 2018-2023
Table 8. Global Companies Anti-cancer Drug Exposure Evaluation Services Product Type
Table 9. List of Global Tier 1 Anti-cancer Drug Exposure Evaluation Services Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Anti-cancer Drug Exposure Evaluation Services Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Anti-cancer Drug Exposure Evaluation Services Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Anti-cancer Drug Exposure Evaluation Services Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Anti-cancer Drug Exposure Evaluation Services Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Anti-cancer Drug Exposure Evaluation Services Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Anti-cancer Drug Exposure Evaluation Services Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Anti-cancer Drug Exposure Evaluation Services Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2024-2029
Table 30. IQVIA Company Summary
Table 31. IQVIA Anti-cancer Drug Exposure Evaluation Services Product Offerings
Table 32. IQVIA Anti-cancer Drug Exposure Evaluation Services Revenue (US$, Mn) & (2018-2023)
Table 33. IQVIA Key News & Latest Developments
Table 34. Labcorp Company Summary
Table 35. Labcorp Anti-cancer Drug Exposure Evaluation Services Product Offerings
Table 36. Labcorp Anti-cancer Drug Exposure Evaluation Services Revenue (US$, Mn) & (2018-2023)
Table 37. Labcorp Key News & Latest Developments
Table 38. PPD Company Summary
Table 39. PPD Anti-cancer Drug Exposure Evaluation Services Product Offerings
Table 40. PPD Anti-cancer Drug Exposure Evaluation Services Revenue (US$, Mn) & (2018-2023)
Table 41. PPD Key News & Latest Developments
Table 42. ICON Company Summary
Table 43. ICON Anti-cancer Drug Exposure Evaluation Services Product Offerings
Table 44. ICON Anti-cancer Drug Exposure Evaluation Services Revenue (US$, Mn) & (2018-2023)
Table 45. ICON Key News & Latest Developments
Table 46. Parexel Company Summary
Table 47. Parexel Anti-cancer Drug Exposure Evaluation Services Product Offerings
Table 48. Parexel Anti-cancer Drug Exposure Evaluation Services Revenue (US$, Mn) & (2018-2023)
Table 49. Parexel Key News & Latest Developments
Table 50. Celerion Company Summary
Table 51. Celerion Anti-cancer Drug Exposure Evaluation Services Product Offerings
Table 52. Celerion Anti-cancer Drug Exposure Evaluation Services Revenue (US$, Mn) & (2018-2023)
Table 53. Celerion Key News & Latest Developments
Table 54. Syneos Health Company Summary
Table 55. Syneos Health Anti-cancer Drug Exposure Evaluation Services Product Offerings
Table 56. Syneos Health Anti-cancer Drug Exposure Evaluation Services Revenue (US$, Mn) & (2018-2023)
Table 57. Syneos Health Key News & Latest Developments
Table 58. WuXi AppTec Company Summary
Table 59. WuXi AppTec Anti-cancer Drug Exposure Evaluation Services Product Offerings
Table 60. WuXi AppTec Anti-cancer Drug Exposure Evaluation Services Revenue (US$, Mn) & (2018-2023)
Table 61. WuXi AppTec Key News & Latest Developments
Table 62. Frontage Laboratories Company Summary
Table 63. Frontage Laboratories Anti-cancer Drug Exposure Evaluation Services Product Offerings
Table 64. Frontage Laboratories Anti-cancer Drug Exposure Evaluation Services Revenue (US$, Mn) & (2018-2023)
Table 65. Frontage Laboratories Key News & Latest Developments
List of Figures
Figure 1. Anti-cancer Drug Exposure Evaluation Services Segment by Type in 2022
Figure 2. Anti-cancer Drug Exposure Evaluation Services Segment by Application in 2022
Figure 3. Global Anti-cancer Drug Exposure Evaluation Services Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Anti-cancer Drug Exposure Evaluation Services Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Anti-cancer Drug Exposure Evaluation Services Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Anti-cancer Drug Exposure Evaluation Services Revenue in 2022
Figure 8. By Type - Global Anti-cancer Drug Exposure Evaluation Services Revenue Market Share, 2018-2029
Figure 9. By Application - Global Anti-cancer Drug Exposure Evaluation Services Revenue Market Share, 2018-2029
Figure 10. By Type - Global Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Anti-cancer Drug Exposure Evaluation Services Revenue Market Share, 2018-2029
Figure 12. By Application - Global Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Anti-cancer Drug Exposure Evaluation Services Revenue Market Share, 2018-2029
Figure 14. By Region - Global Anti-cancer Drug Exposure Evaluation Services Revenue Market Share, 2018-2029
Figure 15. By Country - North America Anti-cancer Drug Exposure Evaluation Services Revenue Market Share, 2018-2029
Figure 16. US Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Anti-cancer Drug Exposure Evaluation Services Revenue Market Share, 2018-2029
Figure 20. Germany Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 21. France Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Anti-cancer Drug Exposure Evaluation Services Revenue Market Share, 2018-2029
Figure 28. China Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 32. India Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Anti-cancer Drug Exposure Evaluation Services Revenue Market Share, 2018-2029
Figure 34. Brazil Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Anti-cancer Drug Exposure Evaluation Services Revenue Market Share, 2018-2029
Figure 37. Turkey Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Anti-cancer Drug Exposure Evaluation Services Revenue, (US$, Mn), 2018-2029
Figure 41. IQVIA Anti-cancer Drug Exposure Evaluation Services Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Labcorp Anti-cancer Drug Exposure Evaluation Services Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. PPD Anti-cancer Drug Exposure Evaluation Services Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. ICON Anti-cancer Drug Exposure Evaluation Services Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Parexel Anti-cancer Drug Exposure Evaluation Services Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Celerion Anti-cancer Drug Exposure Evaluation Services Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Syneos Health Anti-cancer Drug Exposure Evaluation Services Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. WuXi AppTec Anti-cancer Drug Exposure Evaluation Services Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Frontage Laboratories Anti-cancer Drug Exposure Evaluation Services Revenue Year Over Year Growth (US$, Mn) & (2018-2023)